
At its 1163rd meeting, on 16 March 1999, the Commission on Narcotic Drugs decided to include 7,8-dihydro-7-a-[1-(R)-hydroxy-1-methylbutyl]-6,14-endo-ethanotetrahydrooripavine (also known as dihydroetorphine) and 1-(2-methoxycarbonyl-ethyl)-4-(phenylpro-pionylamino)-piperidine-4-carboxylic acid methyl ester (also known as remifentanil) in Schedule I of the Single Convention on Narcotic Drugs of 1961 and that Convention as amended by the 1972 Protocol.